Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC
Stéphane Champiat(The University of Texas MD Anderson Cancer Center), Jean‐Charles Soria(Inserm), Benjamin Besse(Institut Gustave Roussy), Alexander M.M. Eggermont(University Medical Center Utrecht), Ecaterina Ileana(Centre National de la Recherche Scientifique), Giannis Mountzios(Henry Dunant Hospital), Giuseppe Giaccone(Cornell University)
Cited by 96
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k